Loading...
Market
What strategic response will AstraZeneca take in China by March 31, 2025?
2
Resolution / Starting Odds
Increase investment in China • 25%
Reduce operations in China • 25%
No change in strategy • 25%
Other strategic response • 25%
Official announcements from AstraZeneca or industry reports
Story
AstraZeneca's China President and EVP Leon Wang Under Investigation; Shares Drop 3.5%
Oct 30, 2024, 02:00 PM
AstraZeneca announced at 9:00am that its China President and Executive Vice President of International, Leon Wang, is currently under investigation by Chinese authorities and is cooperating with the inquiry. The company's China operations will continue under the leadership of the current general manager. Following the announcement, AstraZeneca's shares dropped by 3.5%.
View original story
Similar markets
Restructuring of Chinese operations • 25%
Increased compliance measures • 25%
Leadership changes • 25%
No significant changes • 25%
No charges filed • 25%
Fines imposed • 25%
Executives prosecuted • 25%
Other • 25%
Yes • 50%
No • 50%
Increase investments in compliance • 25%
Launch new competitive strategies • 25%
No major changes • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Acquisition of another company • 25%
Launch of a new drug • 25%
Restructuring or cost-cutting measures • 25%
Other strategic move • 25%
Strengthen compliance measures • 25%
Increase diplomatic engagement • 25%
No significant changes • 25%
Other strategic changes • 25%
Company A • 25%
Company B • 25%
Company C • 25%
Other • 25%